Literature DB >> 24522831

Lipoxin A4 inhibits NF-κB activation and cell cycle progression in RAW264.7 cells.

Yong-Hong Huang1, Hong-Mei Wang, Zhen-Yu Cai, Fang-Yun Xu, Xiao-Yan Zhou.   

Abstract

Lipoxins (LXs), including lipoxin A4 (LXA4), etc., have been approved for potent anti-inflammatory and immunomodulatory properties. Based on the important roles of macrophages in inflammation and immunomodulation, we investigate the effects of LXA4 on lipopolysaccharide (LPS)-induced proliferation and the possible signal transduction pathways in RAW264.7 macrophages. RAW264.7 cells were treated in vitro with or without LPS in the absence or presence of LXA4. [(3)H]-TdR incorporation assay and flow cytometry were used for detecting cell proliferation and cycle, respectively. Moreover, Western blot was applied to evaluate the protein expression levels of Cyclin E, IκBα, nuclear factor-κB (NF-κB), and IκB kinase (IKK). Our research showed that LXA4 suppressed LPS-induced proliferation, increased the proportion of the G0/G1 phase, decreased the proportion of the S phase, and downregulated the expression of Cyclin E. Besides these, LXA4 suppressed LPS-induced IκBα degradation, NF-κB translocation, and the expression of IKK. The data suggested that LXA4 inhibited LPS-induced proliferation through the G0/G1 phase arrest in RAW264.7 macrophages, and the inhibitory effect might depend on NF-κB signaling transduction pathway.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24522831     DOI: 10.1007/s10753-014-9832-2

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  44 in total

1.  Regulation of lung fibroblast activation by annexin A1.

Authors:  Yuan Jia; Eric F Morand; Wuqi Song; Qiang Cheng; Alastair Stewart; Yuan H Yang
Journal:  J Cell Physiol       Date:  2013-02       Impact factor: 6.384

2.  Pro-resolution mediator lipoxin A4 and its receptor in upper airway inflammation.

Authors:  Shino Shimizu; Takao Ogawa; Satoshi Seno; Hideaki Kouzaki; Takeshi Shimizu
Journal:  Ann Otol Rhinol Laryngol       Date:  2013-11       Impact factor: 1.547

3.  Lipoxin a4 increases survival by decreasing systemic inflammation and bacterial load in sepsis.

Authors:  Jean Walker; Eric Dichter; Grace Lacorte; David Kerner; Bernd Spur; Ana Rodriguez; Kingsley Yin
Journal:  Shock       Date:  2011-10       Impact factor: 3.454

4.  Posttreatment with aspirin-triggered lipoxin A4 analog attenuates lipopolysaccharide-induced acute lung injury in mice: the role of heme oxygenase-1.

Authors:  Sheng-Wei Jin; Li Zhang; Qin-Quan Lian; Dong Liu; Ping Wu; Shang-Long Yao; Du-Yun Ye
Journal:  Anesth Analg       Date:  2007-02       Impact factor: 5.108

5.  Lipoxin A4 antagonizes cellular and in vivo actions of leukotriene D4 in rat glomerular mesangial cells: evidence for competition at a common receptor.

Authors:  K F Badr; D K DeBoer; M Schwartzberg; C N Serhan
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

6.  Growth inhibitory effects of dihydroartemisinin on pancreatic cancer cells: involvement of cell cycle arrest and inactivation of nuclear factor-kappaB.

Authors:  Hua Chen; Bei Sun; Shuangjia Wang; Shangha Pan; Yue Gao; Xuewei Bai; Dongbo Xue
Journal:  J Cancer Res Clin Oncol       Date:  2009-11-26       Impact factor: 4.553

7.  A novel rat lipoxin A4 receptor that is conserved in structure and function.

Authors:  Nan Chiang; Tomoko Takano; Makoto Arita; Shiro Watanabe; Charles N Serhan
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

8.  Antiinflammatory mediator lipoxin A4 and its receptor in synovitis of patients with rheumatoid arthritis.

Authors:  Atsushi Hashimoto; Izumi Hayashi; Yousuke Murakami; Yoshinori Sato; Hidero Kitasato; Reiko Matsushita; Nobuko Iizuka; Ken Urabe; Moritoshi Itoman; Shunsei Hirohata; Hirahito Endo
Journal:  J Rheumatol       Date:  2007-10-01       Impact factor: 4.666

9.  Infection regulates pro-resolving mediators that lower antibiotic requirements.

Authors:  Nan Chiang; Gabrielle Fredman; Fredrik Bäckhed; Sungwhan F Oh; Thad Vickery; Birgitta A Schmidt; Charles N Serhan
Journal:  Nature       Date:  2012-04-25       Impact factor: 49.962

10.  Aspirin-triggered 15-epi-lipoxin A4 predicts cyclooxygenase-2 in the lungs of LPS-treated mice but not in the circulation: implications for a clinical test.

Authors:  Nicholas S Kirkby; Melissa V Chan; Martina H Lundberg; Karen A Massey; William M B Edmands; Louise S MacKenzie; Elaine Holmes; Anna Nicolaou; Timothy D Warner; Jane A Mitchell
Journal:  FASEB J       Date:  2013-06-21       Impact factor: 5.191

View more
  11 in total

1.  Lipoxin A4 suppresses lipopolysaccharide-induced hela cell proliferation and migration via NF-κB pathway.

Authors:  Hua Hao; Fen Xu; Jian Hao; Yuan-Qiao He; Xiao-Yan Zhou; Hua Dai; Li-Qing Wu; Fan-Rong Liu
Journal:  Inflammation       Date:  2015-02       Impact factor: 4.092

2.  Lipoxin A4 Attenuates Obesity-Induced Adipose Inflammation and Associated Liver and Kidney Disease.

Authors:  Emma Börgeson; Andrew M F Johnson; Yun Sok Lee; Andreas Till; Gulam Hussain Syed; Syed Tasadaque Ali-Shah; Patrick J Guiry; Jesmond Dalli; Romain A Colas; Charles N Serhan; Kumar Sharma; Catherine Godson
Journal:  Cell Metab       Date:  2015-06-04       Impact factor: 27.287

3.  Lipoxin A4 pretreatment mitigates skeletal muscle ischemia-reperfusion injury in rats.

Authors:  Haiyang Zong; Xinghui Li; Haodong Lin; Chunlin Hou; Fenfen Ma
Journal:  Am J Transl Res       Date:  2017-03-15       Impact factor: 4.060

Review 4.  Understanding the Mysterious M2 Macrophage through Activation Markers and Effector Mechanisms.

Authors:  Tamás Rőszer
Journal:  Mediators Inflamm       Date:  2015-05-18       Impact factor: 4.711

5.  Nrf2-mediated mucoprotective and anti-inflammatory actions of Artemisia extracts led to attenuate stress related mucosal damages.

Authors:  Jong-Min Park; Young-Min Han; Jin-Seok Lee; Kwang Hyun Ko; Sung-Pyo Hong; Eun-Hee Kim; Ki-Baik Hahm
Journal:  J Clin Biochem Nutr       Date:  2014-11-28       Impact factor: 3.114

Review 6.  Extracellular Vesicles as Conveyors of Membrane-Derived Bioactive Lipids in Immune System.

Authors:  Krizia Sagini; Eva Costanzi; Carla Emiliani; Sandra Buratta; Lorena Urbanelli
Journal:  Int J Mol Sci       Date:  2018-04-18       Impact factor: 5.923

7.  Bupleurum chinense Polysaccharide Improves LPS-Induced Senescence of RAW264.7 Cells by Regulating the NF-κB Signaling Pathway.

Authors:  Mengran Xu; Shengyang Sun; Junhong Ge; Ye Shen; Tan Li; Xin Sun
Journal:  Evid Based Complement Alternat Med       Date:  2020-12-15       Impact factor: 2.629

8.  Behavioral, Anti-Inflammatory, and Neuroprotective Effects of a Novel FPR2 Agonist in Two Mouse Models of Autism.

Authors:  Claudia Cristiano; Floriana Volpicelli; Marianna Crispino; Enza Lacivita; Roberto Russo; Marcello Leopoldo; Antonio Calignano; Carla Perrone-Capano
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-28

9.  Anti-inflammatory properties of lipoxin A4 protect against diabetes mellitus complicated by focal cerebral ischemia/reperfusion injury.

Authors:  Jiang-Quan Han; Cheng-Ling Liu; Zheng-Yuan Wang; Ling Liu; Ling Cheng; Ya-Dan Fan
Journal:  Neural Regen Res       Date:  2016-04       Impact factor: 5.135

10.  Immunomodulatory Effect of Flavonoids of Blueberry (Vaccinium corymbosum L.) Leaves via the NF-κB Signal Pathway in LPS-Stimulated RAW 264.7 Cells.

Authors:  Dazhi Shi; Mengyi Xu; Mengyue Ren; Enshan Pan; Chaohua Luo; Wei Zhang; Qingfa Tang
Journal:  J Immunol Res       Date:  2017-12-27       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.